GNP 101
Alternative Names: anti-HER2-IFN-beta mutein immunocytokine - Genopharm; GNP-101; trastuzumab-IFN-ß mutein - GenopharmLatest Information Update: 02 Jun 2023
At a glance
- Originator Genopharm
- Class Antineoplastics; Immunotherapies; Interferons; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Apoptosis stimulants; Interferon beta replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 24 May 2023 GNP 101 is available for licensing as of 24 May 2023. http://www.genopharmbio.com/web/home.php?go=page2.0&mid=11 (Genopharm website, May 2023)
- 24 May 2023 Geropharm plans a phase I trial for Breast cancer and Gastric cancer in 2025 (Parenteral) (Geropharm pipeline, May 2023)
- 24 May 2023 Geropharm plans a phase II trial for Breast cancer and Gastric cancer in 2027 (Parenteral) (Geropharm pipeline, May 2023)